Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

Phase 2/3 Completed 240 enrolled University of Maryland, Baltimore Nathan Kline Institute for Psychiatric Research · collab National Institute of Mental Health (NIMH) · collab Sarah Herzog Hospital · collab The Zucker Hillside Hospital · collab University of California, Los Angeles · collab University of Maryland, College Park · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia.

Timeline

Start: 2000-01
Primary completion: 2004-06
Completion: 2004-06

Outcome

Missed primary endpoint

paper There were no significant differences in change in the SANS total score between glycine and placebo subjects or D-cycloserine and placebo subjects. PMID 17898352 ↗

paper There were no significant differences between glycine and placebo or D-cycloserine and placebo subjects on the average cognition z score. PMID 17898352 ↗

Publications

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007 Oct;164(10):1593-602. doi: 10.1176/appi.ajp.2007.06081358.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cycloserine	Small molecule	—	—
Subject	Glycine	Other / unclassified	—	—